Who are Monoket Pill's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Monoket, Nitroglycerin, NITROGLYCERIN, Isobide, intravenous nitroglycerin, Nitro-Bid 2 % Topical Ointment.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/monoket-pill.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Monoket Pill — Competitive Intelligence Brief

Monoket Pill (Monoket Pill) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nitrate vasodilator. Area: Cardiovascular.

marketed Nitrate vasodilator Soluble guanylate cyclase (via nitric oxide) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Monoket Pill (Monoket Pill) — Ohio State University. Monoket is an isosorbide mononitrate that releases nitric oxide to dilate blood vessels and reduce cardiac workload in angina.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Monoket Pill TARGET	Monoket Pill	Ohio State University	marketed	Nitrate vasodilator	Soluble guanylate cyclase (via nitric oxide)
Monoket	ISOSORBIDE MONONITRATE		marketed	Nitrate Vasodilator [EPC]	Atrial natriuretic peptide receptor 1	1991-01-01
Nitroglycerin	glyceryl trinitrate	Fougera	marketed	Nitrate Vasodilator [EPC]	guanylate cyclase	1981-01-01
NITROGLYCERIN	NITROGLYCERIN		marketed	Nitrate Vasodilator [EPC]	Nitric oxide synthase pathway	1981-01-01
Isobide	ISOSORBIDE	Novartis	marketed	Nitrate Vasodilator [EPC]		1974-01-01
intravenous nitroglycerin	intravenous nitroglycerin	University of California, San Francisco	marketed	Nitrate vasodilator	Soluble guanylate cyclase (via nitric oxide)
Nitro-Bid 2 % Topical Ointment	Nitro-Bid 2 % Topical Ointment	University of Virginia	marketed	Nitrate vasodilator	Guanylate cyclase (via nitric oxide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-03-12 — Nitroglycerin · 7872049 · US
2029-03-12 — NITROGLYCERIN · 7872049 · Formulation · US
2032-03-11 — Nitroglycerin · 9101592 · US
2032-03-11 — NITROGLYCERIN · 9101592 · Formulation · US

Sponsor landscape (Nitrate vasodilator class)

Aultman Health Foundation · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
GF Strong Rehabilitation Centre · 1 drug in this class
Instituto de Cardiologia de Santa Catarina · 1 drug in this class
MediQuest Therapeutics · 1 drug in this class
Ohio State University · 1 drug in this class
Onze Lieve Vrouwe Gasthuis · 1 drug in this class
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
Recep Tayyip Erdogan University · 1 drug in this class
Soroka University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Monoket Pill — Competitive Intelligence Brief. https://druglandscape.com/ci/monoket-pill. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab